Updates in Treating Sebaceous Carcinoma: Surgical and Adjuvant Options

Sebaceous carcinoma, a rare and aggressive skin cancer arising from sebaceous glands, poses significant treatment challenges for dermatologists. Recent advancements in surgical techniques and adjuvant therapies are enhancing management strategies and improving patient outcomes. This article discusses the current landscape of treatment options for sebaceous carcinoma. Surgical Treatment Approaches Traditionally, the primary treatment for sebaceous carcinoma has been surgical excision. However, the intricacies of this malignancy often necessitate more refined approaches to ensure complete resection and minimize recurrence. Mohs micrographic surgery (MMS) has emerged as the gold standard for treating sebaceous carcinoma, given its ability to ensure clear margins while preserving surrounding healthy tissue. Mohs Micrographic Surgery MMS involves the stepwise removal and immediate pathological examination of tumor layers to confirm complete excision. This technique is especially beneficial in cosmetically sensitive areas, such as the eyelids and face, where preserving surrounding tissue is crucial. Studies have shown that MMS significantly reduces the rate of local recurrence compared to traditional excisional surgery. Adjuvant Therapies While surgical intervention remains the cornerstone of treatment, adjuvant therapies are playing an increasingly important role in the management of sebaceous carcinoma, especially in cases with high risk of recurrence or metastasis. These therapies include radiation, immunotherapy, and targeted therapies, each offering unique benefits. Radiation Therapy Radiation therapy may be considered post-operatively in cases where surgical margins are unclear or in patients who are not surgical candidates due to comorbidities. Studies have indicated that adjuvant radiation can reduce local recurrence rates and improve overall survival in patients with advanced disease. Immunotherapy Recent research has explored the role of immunotherapy, particula